Anti-C1q Antibodies Are Associated With Systemic Lupus Erythematosus Global Activity but Not Specifically With Nephritis A Controlled Study of 126 Consecutive Patients
Anti-C1q Antibodies Are Associated With Systemic Lupus Erythematosus Global Activity but Not Specifically With Nephritis A Controlled Study of 126 Consecutive Patients
复制标题
DOI：
10.1002/art.30401
复制
发表时间：
2011-08-01
影响因子：
--
通讯作者：
Yamanaka, Hisashi
中科院分区：
文献类型：
--
作者：
Katsumata, Yasuhiro;Miyake, Kohei;Yamanaka, Hisashi
Objective.一些研究表明，抗C1q抗体与系统性红斑狼疮（SLE）肾炎的发生和活动相关。然而，抗C1q抗体在SLE中的意义尚未得到充分的表征。本研究的目的是探讨抗C1q抗体与SLE的临床和血清学参数之间的关系。采用酶联免疫吸附试验试剂盒检测2007年至2009年连续入住我校医院的126例活动性SLE患者血清中的抗C1q抗体。在治疗后重新评价初始评价时抗C1q抗体滴度高的患者（n = 20）的血清。对照血清获自患有其他自身免疫性疾病的患者和正常健康对照受试者（每组n = 20）。统计分析抗C1q抗体与SLE临床及血清学指标的关系。126例SLE患者中79例检测到抗C1q抗体。SLE患者抗C1q抗体的阳性率和滴度显著高于类风湿关节炎、系统性硬化症和正常对照组（P < 0.0001）。抗C1q抗体的患病率和滴度与活动性狼疮肾炎无显著相关性（分别为P = 0.462和P = 0.366）。抗C1q抗体滴度与SLE疾病活动指数2000评分和抗双链DNA抗体、C3、C4、CH50和C1q水平显著相关（所有比较P < 0.0001）。此外，随着临床病情的改善，抗C1q抗体滴度也显著下降（P = 0.00097）。这些结果表明，抗C1q抗体与SLE的全球活动，但不具体与活动性狼疮肾炎。
Objective. Several studies have shown that anti-C1q antibodies correlate with the occurrence and activity of nephritis in systemic lupus erythematosus (SLE). However, the significance of anti-C1q antibodies in SLE has not been fully characterized. The aim of this study was to investigate associations between anti-C1q antibodies and clinical and serologic parameters of SLE.Methods. An enzyme-linked immunosorbent assay kit was used to measure anti-C1q antibodies in the sera of 126 consecutive patients with active SLE who were admitted to our university hospital from 2007 through 2009. Sera obtained from patients with high titers of anti-C1q antibodies at the initial evaluation (n = 20) were reevaluated following treatment. Control sera were obtained from patients with other autoimmune diseases and from normal healthy control subjects (n = 20 in each group). Associations between anti-C1q antibodies and clinical and serologic parameters of SLE were statistically analyzed.Results. Anti-C1q antibodies were detected in the sera of 79 of 126 patients with SLE. The prevalence and titers of anti-C1q antibodies were significantly (P < 0.0001) higher in SLE patients than in patients with rheumatoid arthritis, patients with systemic sclerosis, and normal healthy control subjects. The prevalence and titers of anti-C1q antibodies were not significantly associated with active lupus nephritis (P = 0.462 and P = 0.366, respectively). Anti-C1q antibody titers were significantly correlated with SLE Disease Activity Index 2000 scores and the levels of anti-double-stranded DNA antibodies, C3, C4, CH50, and C1q (P < 0.0001 for all comparisons). Moreover, anti-C1q antibody titers significantly decreased as clinical disease was ameliorated following treatment (P = 0.00097).Conclusion. These findings indicate that anti-C1q antibodies are associated with SLE global activity but not specifically with active lupus nephritis.